UMass Chan Receives $2.2 Million to Fund Gene Therapy for Cockayne Syndrome

UMass Chan Medical School has received $2.2 million from a nonprofit patient-advocacy organization to contract with Andelyn Biosciences to manufacture clinical grade AAV9-CSA vector to treat Cockayne syndrome.

Please click here to be taken to the external linkDownload

News & Press Releases

Press Release

November 17, 2025

Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101
Press Release

September 3, 2025

Andelyn Biosciences and Tern Therapeutics Partner for Late-Stage Process Performance Qualification (PPQ) Manufacturing of AAV Gene Therapy for the Treatment of CLN2 Batten DiseaseAndelyn Biosciences and Tern Therapeutics Partner for Late-Stage Process Performance Qualification (PPQ) Manufacturing of AAV Gene Therapy for the Treatment of CLN2 Batten Disease
Press Release

August 21, 2025

Andelyn Biosciences and Amplo Biotechnology Partner to Manufacture Novel Gene Therapies for Diseases Affecting the Neuromuscular JunctionAndelyn Biosciences and Amplo Biotechnology Partner to Manufacture Novel Gene Therapies for Diseases Affecting the Neuromuscular Junction

May 12, 2025

Andelyn Biosciences Applies the AAV Curator® Platform to Deliver Novel Gene Therapy for an Ultra-Rare NEDAMSS Disease Patient 14-Months after DiagnosisAndelyn Biosciences Applies the AAV Curator® Platform to Deliver Novel Gene Therapy for an Ultra-Rare NEDAMSS Disease Patient 14-Months after Diagnosis
View All News & Press Releases
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
PreferencesDenyAccept